1. Scrip
  2. >>Business

Oxford’s PepGen Launches Into DMD With Next-Gen Oligonucleotide Platform

Aims To Challenge Sarepta

 
• By Andrew McConaghie

Arising from an Oxford and Cambridge university collaboration, the spin-out has selected Duchenne muscular dystrophy as the first target for its peptide platform.

Caroline Godfrey
PepGen's chief executive Caroline Godfrey.

New UK biotech company PepGen has raised $45m in Series A funding and has unveiled Duchenne muscular dystrophy (DMD) as the first target for its next-generation oligonucleotide platform.

Spun out two years ago from Oxford University with funding from Oxford Science Innovation (OSI), PepGen’s financing has been led...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Deal Watch: Lilly Teams With GPCR-Focused Superluminal In Cardiometabolic Disease

 
• By Joseph Haas

Plus deals involving Basilea/Venatorx, CorMedix/Melinta, SERB/Y-mAbs, XOMA/Lava, XOMA/Hillevax, MaxCyte/Adicet/Anocca and Bausch Health/DURECT.

Lilly Begins Rebalancing US/Ex-US Drug Costs By Raising Prices In Europe

 
• By Mandy Jackson

Lilly said prices governments pay in developed countries, including those in Europe, need to increase to make US drug prices lower, rebalancing costs as CEO David Ricks recently advocated.

Schrödinger Drops CDC7 Inhibitor SGR-2921 After Two Patient Deaths

 
• By Alaric DeArment

The drug is one of multiple candidates in the class that have been pulled from development, though it is not the company’s lead candidate.